Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > LATEST
LATEST
-
BUSINESS Lilly, Nippon Shinyaku Pair Up on Blood Cancer Med in Japan
March 26, 2024
-
REGULATORY Japan’s 1st Eylea Biosimilar Approval on Horizon? JAN Now Decided
March 25, 2024
-
BUSINESS Daiichi Sankyo Eyes 7 Additional Indications for Enhertu by 2026
March 25, 2024
-
BUSINESS Ono Hooks Up with Oxford on Drug Discovery Research
March 25, 2024
-
BUSINESS EMA Delays Decision on Leqembi Due to Procedural Issues
March 25, 2024
-
BUSINESS Iclusig Gets Additional FDA Nod for Iclusig in Ph+ ALL: Takeda
March 25, 2024
-
BUSINESS Novartis, Sandoz Recall Entacapone Products over Carcinogenic Risk
March 25, 2024
-
BUSINESS Kobayashi Pharma Recalls Supplements on Reports of Kidney Disorders
March 25, 2024
-
REGULATORY Chuikyo Agrees to Exempt PD-1/PD-L1, JAK Classes from Spillover Re-Pricing
March 25, 2024
-
REGULATORY Xocova’s Price to Remain Intact after Full Approval, No Change in Clinical Positioning
March 25, 2024
-
REGULATORY Japan Set to Push Central IRBs for Clinical Trials, Avoid Customary All-Case PMS
March 22, 2024
-
REGULATORY Pharma Regulation Panel Wraps Up Debate, Report to Be Finalized Soon
March 22, 2024
-
BUSINESS Japan, US CROs to Collaborate to Address Drug Lags/Losses
March 22, 2024
-
BUSINESS Astellas Gives 1.5% Pay Raise to Acquire Best Talents
March 22, 2024
-
REGULATORY 1 Year on, China Mulling Potential Indictment of Detained Astellas Employee
March 22, 2024
-
ORGANIZATION FPMAJ Lays Out Planned Activities for FY2024
March 22, 2024
-
ORGANIZATION Scrap Off-Year Drug Revision as It Mars Innovation, Supply: JPMA Official
March 22, 2024
-
BUSINESS FDA Clears Orchard’s Lenmeldy Gene Therapy for MLD
March 22, 2024
-
REGULATORY Japan Awards Orphan Tag to Janssen’s Talquetamab, 2 More APIs
March 22, 2024
-
COLUMN How to Paint an Irresistible Picture of Success
March 22, 2024
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…